The combination of sintilimab, a selective anti-PD-1 antibody (Figure 6A), plus IBI305, a bevacizumab biosimilar, has been assessed as a first-line treatment of advanced HCC in a randomized, open-label, phase II/III study (ORIENT-32). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.